RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Clinical trials for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA explained in plain language.
Never miss a new study
Get alerted when new RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA trials appear
Sign up with your email to follow new studies for RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer: targeted drug trial opens
Disease control Recruiting nowThis study tests a drug called mirdametinib in people whose chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) has returned or stopped responding to treatment. The drug blocks a protein that helps cancer cells grow. About 20 participants will take the drug to …
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: National Cancer Institute (NCI) • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
Engineered immune cells take on tough blood cancers in early trial
Disease control Recruiting nowThis early-stage trial tests a new treatment called IC19/1563 for people with certain blood cancers (like lymphoma or leukemia) that have returned or not improved after standard therapy. The treatment uses a patient's own immune cells, which are modified in a lab to better recogn…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 13:04 UTC
-
Triple-Target CAR T-Cells offer new hope for tough blood cancers
Disease control Recruiting nowThis early-stage trial tests a new type of cell therapy for people with certain blood cancers (like lymphoma, leukemia) that have returned or stopped responding to standard treatments. The therapy uses a patient's own immune cells, which are genetically modified to recognize and …
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Sumithira Vasu • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New drug cocktail aims to wipe out Hard-to-Treat blood cancers
Disease control Recruiting nowThis Phase 2 trial tests a combination of two oral drugs, acalabrutinib and venetoclax, in 20 adults with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) that has come back or not responded to treatment. The goal is to see if the combo can reduce cancer cel…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:34 UTC
-
New combo therapy aims to speed up treatment for blood cancer patients
Disease control Recruiting nowThis study tests a faster, hospital-based dose increase of the drug sonrotoclax for people with chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL), or mantle cell lymphoma (MCL) that is new, has returned, or hasn't responded to treatment. Participants first rece…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: Fred Hutchinson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:23 UTC
-
New cocktail of cancer drugs shows promise for tough leukemia cases
Disease control Recruiting nowThis phase 2 trial is testing whether a combination of three drugs—acalabrutinib, venetoclax, and obinutuzumab—can better control chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) that has come back or is resistant to treatment. About 168 adults with high-ri…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE2 • Sponsor: M.D. Anderson Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Triple-Target CAR t cells take on tough blood cancers
Disease control Recruiting nowThis early-phase trial tests a new type of immunotherapy called TriCAR19.20.22 T cells for people with certain blood cancers (non-Hodgkin lymphoma, acute lymphoblastic leukemia, and chronic lymphocytic leukemia) that have returned or not responded to standard treatments. The ther…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Ohio State University Comprehensive Cancer Center • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC
-
Engineered immune cells take on Hard-to-Treat blood cancers
Disease control Recruiting nowThis early-phase trial is testing a new type of CAR T-cell therapy called MC10029 for people with B-cell blood cancers that have returned or not responded to treatment. The therapy involves taking a patient's own immune cells, modifying them in the lab to target a protein called …
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 09:05 UTC
-
New pill Q702 aims to outsmart blood cancers in early trial
Disease control Recruiting nowThis early-stage trial is testing a new drug called Q702 in people with various blood cancers and related disorders that have not responded to standard treatments. Q702 is designed to help the immune system attack cancer cells and help the bone marrow make healthy blood cells. Th…
Matched conditions: RECURRENT CHRONIC LYMPHOCYTIC LEUKEMIA
Phase: PHASE1 • Sponsor: Mayo Clinic • Aim: Disease control
Last updated Jun 27, 2026 07:54 UTC